Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Bertrand_Duchêne
|
| gptkbp:country |
gptkb:France
|
| gptkbp:developedBy |
microbiome-based drugs
|
| gptkbp:focusesOn |
therapeutics
gut microbiome |
| gptkbp:foundedYear |
2010
|
| gptkbp:headquartersLocation |
gptkb:Bordeaux,_France
|
| https://www.w3.org/2000/01/rdf-schema#label |
LNC Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:researchInterest |
obesity
metabolic diseases metabolic disorders |
| gptkbp:specializesIn |
Akkermansia muciniphila research
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.lnctherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Seventure_Partners
|
| gptkbp:bfsLayer |
6
|